The GLP-1 fusion peptide was shown to improve glucose tolerance in both models of DM [46, 47] and the exendin-4 fusion peptide was also shown to improve glucose homeostasis and ameliorate T1 DM symptoms when tested in mice treated with chronic low doses of streptozotocin [46]. The gene discussed is GLP1R; the disease is diabetes mellitus.